Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis

被引：0
|
作者：
Gao Xiang
Min Gao
Huirong Qin
Xiaolan Shen
Huilian Huang
Xiaoqiang Hou
Zhitao Feng
机构：
[1] China Three Gorges University,The First College of Clinical Medical Sciences
[2] Yichuan Community Health Service Center,Third
[3] Affiliated Renhe Hospital of China Three Gorges University,Grade Pharmacological Laboratory On Chinese Medicine Approved By State Administration of Traditional Chinese Medicine
[4] Institute of Rheumatology,undefined
[5] the First College of Clinical Medical Sciences,undefined
[6] China Three Gorges University,undefined
[7] Medical College of China Three Gorges University,undefined
来源：
BMC Complementary Medicine and Therapies | / 23卷
关键词：
Sinomenine; Traditional Chinese medicine; Rheumatoid arthritis; Benefit-risk assessment; Multicriteria decision analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
    Xiang, Gao
    Gao, Min
    Qin, Huirong
    Shen, Xiaolan
    Huang, Huilian
    Hou, Xiaoqiang
    Feng, Zhitao
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [2] A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment
    Saint-Hilary, Gaelle
    Cadour, Stephanie
    Robert, Veronique
    Gasparini, Mauro
    BIOMETRICAL JOURNAL, 2017, 59 (03) : 567 - 578
  • [3] Comprehensive Benefit-Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis
    Sidi, Yulia
    Harel, Ofer
    VALUE IN HEALTH, 2020, 23 (12) : 1622 - 1629
  • [4] SENSITIVITY ANALYSIS IN MULTI-CRITERIA DECISION (MCDA) MODELS FOR BENEFIT-RISK ASSESSMENT
    Ijzerman, M. J.
    Groothuis-Oudshoorn, K.
    Hummel, J. M.
    VALUE IN HEALTH, 2011, 14 (07) : A424 - A424
  • [5] Multicriteria benefit-risk assessment using network meta-analysis
    van Valkenhoef, Gert
    Tervonen, Tommi
    Zhao, Jing
    de Brock, Bert
    Hillege, Hans L.
    Postmus, Douwe
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2012, 65 (04) : 394 - 403
  • [6] Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis
    Mikuls, TR
    Moreland, LW
    DRUG SAFETY, 2003, 26 (01) : 23 - 32
  • [7] Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
    Ted R. Mikuls
    Larry W. Moreland
    Drug Safety, 2003, 26 : 23 - 32
  • [8] A benefit-risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients
    Byun, Ji-Hye
    Kwon, Sun-Hong
    Ha, Ji-Hye
    Lee, Eui-Kyung
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 965 - 974
  • [9] Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
    Vermersch, Patrick
    Martinelli, Vittorio
    Pfleger, Claudia
    Rieckmann, Peter
    Alonso-Magdalena, Lucia
    Galazka, Andrew
    Dangond, Fernando
    Phillips, Lawrence
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 249 - 260
  • [10] Benefit-Risk Assessment of Chinese Medicine Injections for Primary Liver Cancer Based on Multi-criteria Decision Analysis
    ZHANG Rongrong
    SHAO Mingyi
    FU Yu
    ZHAO Ruixia
    WANG Jingwen
    FANG Yuxuan
    Chinese Journal of Integrative Medicine, 2024, 30 (06) : 559 - 564
12345